NeuralStem, a Rockville, MD biotech, has received FDA approval to proceed with a small phase I safety study of its fetal neural stem cells in patients with ALS (Lou Gehrig's Disease).
This trial, originally placed on hold by the FDA last February, is not intended to show whether or not the transplanted cells protect the motor neurons threatened by the disease, only whether or not they are safe for the patient undergoing treatment.
Read the story on Nature.com.
Read more about stem cells and SCI.Susan P. Howley
Executive Vice President, Research
Christopher and Dana Reeve Foundation
